Form 4: RAPT Therapeutics Insiders Exchange Common Stock for Pre-Funded Warrants

Several key insiders at RAPT Therapeutics, including Column Group II, LP and Ponoi Capital, LP, exchanged common stock for pre-funded warrants on December 23, 2024.

Summary

• On December 23, 2024, Column Group II, LP and Ponoi Capital, LP exchanged 1,352,008 and 1,599,417 shares of RAPT Therapeutics common stock, respectively, for pre-funded warrants.
• These pre-funded warrants allow the holders to purchase the same number of common stock shares at an exercise price of $0.0001 per share.
• The warrants have no expiration date and can be exercised at any time, subject to a 4.99% ownership limit.
• The transaction was an exchange with no additional consideration paid.
• The reporting parties include various entities and individuals associated with Column Group and Ponoi Capital, all of whom are considered 10% owners of RAPT Therapeutics.

Sentiment

Score: 6

Explanation: The document reflects a standard insider transaction, which is neither particularly positive nor negative. It's a neutral event from an investment perspective.

Positives

• The pre-funded warrants provide flexibility for the holders to acquire shares in the future at a nominal price.
• The absence of an expiration date on the warrants provides long-term optionality for the holders.

Risks

• The exercise of the warrants could potentially dilute existing shareholders if a large number of warrants are exercised at once.
• The 4.99% ownership limit on warrant exercise could restrict the ability of the holders to increase their stake significantly.

Industry Context

This type of transaction is common among venture capital and private equity firms that hold significant stakes in publicly traded companies. It allows them to manage their ownership and potential future investment in the company.

Comparison to Industry Standards

• The exchange of common stock for pre-funded warrants is a relatively common practice in the biotech industry, particularly for companies backed by venture capital firms.
• Similar transactions can be seen with companies like Moderna and BioNTech, where early investors have used warrants and other instruments to manage their holdings.
• The low exercise price of $0.0001 per share is typical for pre-funded warrants, reflecting the early-stage investment and the risk taken by the investors.

Stakeholder Impact

• The transaction could potentially dilute existing shareholders if the warrants are exercised.
• The exchange does not have an immediate impact on the company's operations or financial position.

Key Dates

Keywords

RAPT Therapeutics, pre-funded warrants, common stock, insider trading, Column Group, Ponoi Capital, exchange agreement, beneficial ownership